32 results about "Meclofenoxate Hydrochloride" patented technology

An injection of meclofenoxate hydrochloride and its preparing process which features use of non-water solvent chosen from alcohol, propanediol, glycerin, polyethanediol-300 and polyethanediol-400, and use of filter sterilizing method or wet-heat sterilizing method for high stability are disclosed.

The invention provides a meclofenoxate hydrochloride compound. A structural formula of the meclofenoxate hydrochloride compound is as shown in the specification, and the meclofenoxate hydrochloride compound uses an X-ray powder diffraction spectrogram obtained through Cu-K alpha ray measurement, as shown in Figure 1 in the specification. The invention further provides a preparation method of the meclofenoxate hydrochloride compound, and a pharmaceutical composition containing the meclofenoxate hydrochloride compound. The pharmaceutical composition of the meclofenoxate hydrochloride compound is an aseptic powder injection, a freeze-drying powder injection, a dispersible tablet, a tablet or oral liquid. Compared with the prior art, the meclofenoxate hydrochloride compound and the pharmaceutical composition of the meclofenoxate hydrochloride compound have better storage stability and fluidity, and greatly improve the medication safety of a patient.

The invention relates to a method for preparing a meclofenoxate hydrochloride sterile bulk drug, which is characterized in that a meclofenoxate hydrochloride sterile finished product is obtained by the following steps: dissolving meclofenoxate hydrochloride in isopropanol in a certain mixture ratio, then decoloring and carrying out aseptic filtration and decompression concentration, and then devitrifying, filtering and drying. The product prepared by the method has more stable quality and simple process, thereby being suitable for industrial big production.

The invention discloses a synthetic process of crude meclofenoxate hydrochloride. The synthetic process comprises the following steps: checking and cleaning a detection instrument, production equipment and a working place before production, performing a heating reflux reaction on toluene, tolueneaminoethanol, p-chlorophenoxyacetic acid and toluenesulfonic acid, cooling, decolorizing, performing suction filtration on decolorizing liquid, standing and layering filter liquor, performing suction filtration, immersion cleaning and vacuum drying on upper-layer crystals to prepare crude meclofenoxate hydrochloride, and finally weighing and packaging. According to the synthetic process, high-quality crude meclofenoxate hydrochloride can be prepared, the yield is 74.0%-78.0%, a good foundation is laid for refining meclofenoxate hydrochloride, and the production cost is reduced.

The invention relates to an alcaine methyl chloroformate compound which can avoid hydrolysis. Wherein, said compound comprises active component alcaine methyl chloroformate, findings, lubricant and stabilizer, while the stabilizer can keep the compound at weak acid. And the invention uses full powder compress method to avoid hydrolysis problem.

The invention belongs to the technical field of medicine, and discloses a drug composition of meclofenoxate hydrochloride and polyethylene glycol and a preparation method thereof. The weight ratio of the meclofenoxate hydrochloride and the polyethylene glycol is 1:0.002-0.1. The invention solves the problems that the meclofenoxate hydrochloride is easily hydrolyzed when meeting water and instably stored in the prior art. The drug composition has stable property and convenient storage, and improves the safety of clinical medication.

The present invention relates to a new application of meclofenoxate hydrochloride for preparing medicine for curing necrosis of femoral head with good therapeutic effect. The invented medicine can be made into injection preparation, also can be made into oral preparation, for example meclofenoxate hydrochloride capsule, etc. Said invention also provides its application method.

The invention discloses a purification process of meclofenoxate hydrochloride. The purification process of meclofenoxate hydrochloride includes the following steps that before production, detection instruments, production devices and work sites are detected and cleaned, salt shakers are started in a vacuum state, anhydrous ethanol is sucked into the salt shakers, crude meclofenoxate hydrochloride products are stirred and dissolve in the anhydrous ethanol, medicinal carbon is put into the salt shakers and mixed for decoloration, feed liquid is sterilized and filtered from the salt shakers level by level, input in a crystallization tank, cooled, crystallized and filtered, vacuum drying is conducted after two washing processes are finished, and cooling and discharge can be conducted after it is detected that moisture in crystals is below 0.5%. The purification process is stable, meclofenoxate hydrochloride with high quality and purity can be purified through the crude meclofenoxate hydrochloride products, and the yield can reach 80.0% to 88.0%.

The invention discloses a pharmaceutical meclofenoxate hydrochloride composition for treating pediatric enuresis and belongs to the technical field of medicines. The pharmaceutical meclofenoxate hydrochloride composition consists of meclofenoxate hydrochloride and sodium chloride, wherein meclofenoxate hydrochloride is in the form of crystals, and an X-ray powder diffraction pattern obtained through Cu-K alpha ray measurement is as shown in the Figure 1. The novel crystal form of meclofenoxate hydrochloride, provided by the invention, is different from the crystal form structure in the prior art. Tests verify that the provided meclofenoxate hydrochloride composition is remarkably improved in hygroscopicity and fluidity, extremely low in moisture and impurity content and better in stability than the prior art, and provides convenience for agent preparation. The meclofenoxate hydrochloride composition provided by the invention is higher in bioavailability and lower in side reaction rate than the prior art. A powder injection prepared from the novel crystal form compound is excellent in fluidity, extremely low in moisture and impurity content, better in stability, high in bioavailability and low in side reaction rate.

The invention relates to a central stimulant meclofenoxate hydrochloride composition and belongs to the technical field of medicines. The composition is prepared from meclofenoxate hydrochloride and anhydrous sodium carbonate, wherein the meclofenoxate hydrochloride is crystal and an X-ray powder diffraction pattern obtained through measurement by using Cu-K alpha rays is as shown in picture 1. The new crystal form of the meclofenoxate hydrochloride provided by the invention is different from the crystal form structures in the prior art. As proved by tests, compared with the prior art, the meclofenoxate hydrochloride crystal compound provided by the invention has the advantages that the moisture absorption and flowability are obviously improved, the content of water and impurities is extremely low, the stability is better and convenience is provided for the preparation of preparations. Compared with the prior art, the meclofenoxate hydrochloride crystal compound provided by the invention has higher bioavailability and the side reaction rate is reduced. Compared with the prior art, powder-injection prepared by using the compound of the new crystal form has the advantages of good flowability, extremely low content of water and impurities, better stability, high bioavailability and low side reaction rate.

The invention provides a meclofenoxate hydrochloride medicinal composition and a method for preparing a freeze-drying powder injection of the meclofenoxate hydrochloride medicinal composition. The meclofenoxate hydrochloride medicinal composition comprises the following components in part by weight: 30 to 100 parts of meclofenoxate hydrochloride, 60 to 120 parts of reduced glutathione and 40 to 80 parts of mannitol. The preparation method comprises the following steps of: a) dissolving the mannitol in water for injection, adding the meclofenoxate hydrochloride, and regulating the pH value to be 2-5; b) adding the reduced glutathione, stirring uniformly, adsorbing the solution by using 0.01 percent active carbon and filtering; and c) performing freeze drying to obtain the freeze-drying powder injection. The meclofenoxate hydrochloride medicinal composition has a reasonable formula and a good curative effect, and is high in quality stability, small in side effects and high in safety, and the adverse reaction of patients on medicine is reduced. The method for preparing the freeze-drying powder injection of the meclofenoxate hydrochloride medicinal composition is reasonable, reliable, simple, feasible, and suitable for industrial production.

The invention belongs to the technical field of medicine and relates to a brain neurotrophic drug meclofenoxate hydrochloride composition, comprising meclofenoxate hydrochloride and arginine. The meclofenoxate hydrochloride is a crystal, its X-ray powder diffraction pattern measured using Cu-KAlpha ray is shown as in Figure 1. The novel crystal form of the meclofenoxate hydrochloride is different from prior art crystal form structures, experiments show that the meclofenoxate hydrochloride crystal form compound has significantly improved moisture absorption and fluidity when compared to the prior art, the moisture and impurity content is very low, the stability is better, and the preparation of preparations is facilitated. Compared with the prior art, the meclofenoxate hydrochloride crystal form compound is higher in bioavailability and lower in side effect rate. Compared with the prior art, a powder injection made with the novel crystal from compound has good fluidity, very low moisture and impurity content, better stability, high bioavailability and low side effect rate.

The invention relates to the field of biological pharmacy, in particular to application of meclofenoxate hydrochloride (MH) in preparation of a medicine for preventing or treating Parkinson's disease. By integrating multi-omics data to explore a gene co-expression network and applying cell and animal experiments to verify, the meclofenoxate hydrochloride can obviously prevent synaptic injury caused by mitochondrial function decline in the Parkinson's disease, can effectively reduce mitochondrial membrane injury and reduce mitochondrial edema, and can effectively enable the expression of synapsis specific proteins to rise; it is indicated that the Parkinson's disease characterized by neuronal synaptic lesion can be prevented, dopamine activity is improved, Parkinson's disease lesion is prevented, and behavioral symptoms of the Parkinson's disease is improved.

The invention belongs to the technical field of medicines, and relates to a meclofenoxate hydrochloride dry suspension and a preparation method thereof. The meclofenoxate hydrochloride dry suspension is used for treating traumatic coma, alcoholism, neonatal anoxia and child enuresis. The meclofenoxate hydrochloride dry suspension has a relatively-good taste, is simple and feasible in preparation process, and is more suitable for old patients and child patients when compared with the preparation products on sale at present.

The invention belongs to the technical field of medicine and relates to an orally disintegrating tablet containing meclofenoxate hydrochloride and a preparation method thereof. The orally disintegrating tablet containing meclofenoxate hydrochloride is used for treating traumatic coma, alcoholism, neonatal anoxia and nocturia enuresis. The orally disintegrating tablet containing meclofenoxate hydrochloride tastes good and the preparation technology is simple and feasible. Compared with products available in the market at present, the orally disintegrating tablet containing meclofenoxate hydrochloride is quite suitable for the old, children and patients with dysphagia.

The invention discloses a meclofenoxate hydrochloride pharmaceutical composition capable of promoting brain energy metabolism, and belongs to the technical field of medicines. The composition is prepared from meclofenoxate hydrochloride and sodium dihydrogen phosphate, wherein the meclofenoxate hydrochloride is crystal, and an X-ray powder diffraction pattern obtained by measuring through using a Cu-K alpha ray is shown as a figure 1. The novel crystal form of the meclofenoxate hydrochloride provided by the invention is different from the structure of an existing crystal from in the prior art. Through experimental verification, a meclofenoxate hydrochloride crystal compound provided by the invention is greatly improved in hygroscopicity and fluidity in comparison with those in the prior art, the water content and the impurity content are extremely low, the stability is good, and convenience is brought for the preparation of a preparation.

The invention belongs to the technical field of medicines, and particularly relates to a method for quickly judging the quality condition of the meclofenoxate hydrochloride powder injection. The method comprises the following steps of (1) providing a meclofenoxate hydrochloride powder injection test sample; (2) determining the particle size and the particle size distribution of the test sample by using a laser scattering granularity distribution instrument and a light scattering method, and calculating Dv10, Dv50 and Dv90 values of test sample particles; (3) calculating the span of the test sample powder by the following formula: Span=(Dv90-Dv10)/Dv50; and (4) determining the quality condition of the meclofenoxate hydrochloride powder injection according to the result of the span value. The invention further relates to a method for preparing the meclofenoxate hydrochloride powder injection by virtue of the span parameter value. According to the method provided by the invention, the quality condition of the meclofenoxate hydrochloride powder injection can be quickly judged, and the obtained product has excellent property when the meclofenoxate hydrochloride powder injection is prepared by virtue of the method.